Use of Continuous Intravenous Anakinra Infusion in Multisystem Inflammatory Syndrome in Children.
Abdulaziz AlolayanAbdullah S AldameghAzzah AlkhayratPublished in: Case reports in critical care (2023)
Coronavirus disease (COVID-19) is an emergency pandemic with a high mortality rate worldwide. One of its complications in children is developing multisystemic inflammatory syndrome related to cytokine storm. Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist used to suppress the exaggerated inflammatory response in such conditions, and it is potentially lifesaving in a cytokine storm. We present the case of a patient with critical COVID-19 associated with multisystem inflammatory syndrome in children (MIS-C) successfully treated with anakinra intravenous (IV) infusion.
Keyphrases
- coronavirus disease
- sars cov
- case report
- young adults
- inflammatory response
- oxidative stress
- recombinant human
- respiratory syndrome coronavirus
- low dose
- emergency department
- healthcare
- risk factors
- public health
- cardiovascular disease
- type diabetes
- coronary artery disease
- lipopolysaccharide induced
- lps induced
- toll like receptor
- emergency medical